Logo image of NRXP

NRX PHARMACEUTICALS INC (NRXP) Stock Fundamental Analysis

NASDAQ:NRXP - US6294442099 - Common Stock

2.69 USD
+0.05 (+1.89%)
Last: 8/25/2025, 8:00:02 PM
2.85 USD
+0.16 (+5.95%)
After Hours: 8/25/2025, 8:00:02 PM
Fundamental Rating

1

Overall NRXP gets a fundamental rating of 1 out of 10. We evaluated NRXP against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NRXP have multiple concerns. NRXP has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NRXP had negative earnings in the past year.
NRXP had a negative operating cash flow in the past year.
NRXP had negative earnings in each of the past 5 years.
NRXP had a negative operating cash flow in each of the past 5 years.
NRXP Yearly Net Income VS EBIT VS OCF VS FCFNRXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -698.51%, NRXP is not doing good in the industry: 95.34% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -698.51%
ROE N/A
ROIC N/A
ROA(3y)-418.16%
ROA(5y)-467.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXP Yearly ROA, ROE, ROICNRXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

NRXP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRXP Yearly Profit, Operating, Gross MarginsNRXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for NRXP has been reduced compared to 1 year ago.
The number of shares outstanding for NRXP has been increased compared to 5 years ago.
Compared to 1 year ago, NRXP has a worse debt to assets ratio.
NRXP Yearly Shares OutstandingNRXP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NRXP Yearly Total Debt VS Total AssetsNRXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -105.07, we must say that NRXP is in the distress zone and has some risk of bankruptcy.
NRXP has a worse Altman-Z score (-105.07) than 94.30% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -105.07
ROIC/WACCN/A
WACCN/A
NRXP Yearly LT Debt VS Equity VS FCFNRXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

NRXP has a Current Ratio of 0.11. This is a bad value and indicates that NRXP is not financially healthy enough and could expect problems in meeting its short term obligations.
NRXP has a worse Current ratio (0.11) than 96.37% of its industry peers.
NRXP has a Quick Ratio of 0.11. This is a bad value and indicates that NRXP is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NRXP (0.11) is worse than 96.37% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
NRXP Yearly Current Assets VS Current LiabilitesNRXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

NRXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.59%, which is quite impressive.
EPS 1Y (TTM)45.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 47.41% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.05%
EPS Next 2Y56.54%
EPS Next 3Y47.41%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRXP Yearly Revenue VS EstimatesNRXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
NRXP Yearly EPS VS EstimatesNRXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 2 -2 -4 -6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

NRXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 2.59, which indicates a rather cheap valuation of NRXP.
98.45% of the companies in the same industry are more expensive than NRXP, based on the Price/Forward Earnings ratio.
NRXP is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.63, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 2.59
NRXP Price Earnings VS Forward Price EarningsNRXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXP Per share dataNRXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

NRXP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NRXP's earnings are expected to grow with 47.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.54%
EPS Next 3Y47.41%

More info and screens

0

5. Dividend

5.1 Amount

NRXP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NRX PHARMACEUTICALS INC

NASDAQ:NRXP (8/25/2025, 8:00:02 PM)

After market: 2.85 +0.16 (+5.95%)

2.69

+0.05 (+1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-18 2025-08-18/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners13.34%
Inst Owner Change31%
Ins Owners10.31%
Ins Owner Change0%
Market Cap46.51M
Analysts84
Price Target29.84 (1009.29%)
Short Float %4.23%
Short Ratio2.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.05%
Min EPS beat(2)-49.47%
Max EPS beat(2)31.37%
EPS beat(4)2
Avg EPS beat(4)-19.1%
Min EPS beat(4)-138.39%
Max EPS beat(4)80.09%
EPS beat(8)5
Avg EPS beat(8)-4.18%
EPS beat(12)7
Avg EPS beat(12)-3.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.63%
PT rev (3m)2.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.69%
EPS NY rev (1m)-44%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.59
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)1.04
Fwd EY38.68%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS-2.06
TBVpS-2.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -698.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-418.16%
ROA(5y)-467.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -105.07
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)103.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.73%
EPS Next Y92.05%
EPS Next 2Y56.54%
EPS Next 3Y47.41%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.18%
OCF growth 3YN/A
OCF growth 5YN/A